Contineum Therapeutics (CTNM) Set to Post Quarterly Earnings on Thursday

Contineum Therapeutics (NASDAQ:CTNM) is expected to be announcing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of ($0.45) per share and revenue of $5.65 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 3:00 PM ET.

Contineum Therapeutics (NASDAQ:CTNM) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05. On average, analysts expect Contineum Therapeutics to post ($1.68) EPS for the current fiscal year and ($1.64) EPS for the next fiscal year.

Contineum Therapeutics Trading Up 10.4%

Shares of CTNM opened at $8.99 on Wednesday. The stock has a fifty day moving average price of $13.08 and a two-hundred day moving average price of $13.53. Contineum Therapeutics has a 52-week low of $6.72 and a 52-week high of $17.78.

Analyst Ratings Changes

A number of equities research analysts have commented on CTNM shares. Morgan Stanley decreased their price objective on shares of Contineum Therapeutics from $18.00 to $17.00 and set an “equal weight” rating on the stock in a report on Monday, September 28th. Robert W. Baird downgraded shares of Contineum Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $19.00 to $14.00 in a research note on Tuesday, October 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Thursday, October 15th. Wall Street Zen cut shares of Contineum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Finally, JonesTrading increased their price target on shares of Contineum Therapeutics from $24.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, October 15th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Contineum Therapeutics presently has a consensus rating of “Hold” and an average price target of $22.33.

About Contineum Therapeutics

Contineum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological and neuroinflammatory diseases. The company’s research is centered on restoring nervous-system function and addressing conditions in which inflammation or damage to myelin contributes to disease progression.

Contineum’s lead programs include PIPE-307, an oral, selective M1 muscarinic receptor antagonist being studied for its potential to promote remyelination in multiple sclerosis, and PIPE-791, an oral, central nervous system-penetrant LPA1 antagonist being developed for progressive multiple sclerosis and other fibrotic or neuroinflammatory conditions.